Inclusion Criteria:  50 to 80 years of age Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD according to National Institute of Aging-Alzheimer's Association (NIA-AA) A global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and CDR-Memory Box (CDRMB) score ≥0.5 at Screening and Baseline Score of ≤85 for the delayed recall domain of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Screening Mini-Mental State Examination (MMSE) score ≥20 at Screening Participant has an identified informant that has and will maintain sufficient contact (minimum of 5 hours per week) with the participant to be able to provide accurate information on the participant's cognitive, functional, and emotional states and of the participant's personal care At least 6 years of formal education after the age of 5 or work experience to exclude mental deficits other than prodromal or mild AD dementia Evidence of cerebral Aβ accumulation by either positive amyloid assessment by either positron emission tomography (PET) scan or cerebrospinal fluid pTau181/Aβ1-42 ratio assessment  Exclusion Criteria:  Any evidence of a condition that may affect cognition other than AD Contraindications to PET imaging Inability to tolerate or contraindication to magnetic resonance imaging Any serious medical condition or abnormality that in the opinion of the investigator would preclude safe participation in and completion of the study or interfere with study assessments and/or study interpretation Alcohol or drug abuse within 2 years of screening Use of any experimental therapy within the past 6 months (or 5 half lives) prior to screening Previous treatment with medication intended to treat a neurodegenerative disorder (other than AD) within 1 year of screening Chronic daily treatment with atypical antipsychotics, opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally acting antihistamine or anticholinergic activitiy Received treatment with monoclonal antibodies (mAbs), cytokines, immunoglobulins, or other blood products within 3 months or 5 half-lives (whichever is longer) prior to first dosing